These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 24382093)

  • 1. The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice.
    Rakha EA; Starczynski J; Lee AH; Ellis IO
    Histopathology; 2014 Apr; 64(5):609-15. PubMed ID: 24382093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laboratory compliance with the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 testing guidelines: a 3-year comparison of validation procedures.
    Dyhdalo KS; Fitzgibbons PL; Goldsmith JD; Souers RJ; Nakhleh RE
    Arch Pathol Lab Med; 2014 Jul; 138(7):876-84. PubMed ID: 24978913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.
    Shah SS; Ketterling RP; Goetz MP; Ingle JN; Reynolds CA; Perez EA; Chen B
    Hum Pathol; 2010 Jan; 41(1):103-6. PubMed ID: 19762065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 testing: current status and future directions.
    Perez EA; Cortés J; Gonzalez-Angulo AM; Bartlett JM
    Cancer Treat Rev; 2014 Mar; 40(2):276-84. PubMed ID: 24080154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
    Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
    Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization.
    Bethune GC; Veldhuijzen van Zanten D; MacIntosh RF; Rayson D; Younis T; Thompson K; Barnes PJ
    Histopathology; 2015 Dec; 67(6):880-7. PubMed ID: 25913507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria.
    Schalper KA; Kumar S; Hui P; Rimm DL; Gershkovich P
    Arch Pathol Lab Med; 2014 Feb; 138(2):213-9. PubMed ID: 24164555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated UK Recommendations for HER2 assessment in breast cancer.
    Rakha EA; Pinder SE; Bartlett JM; Ibrahim M; Starczynski J; Carder PJ; Provenzano E; Hanby A; Hales S; Lee AH; Ellis IO;
    J Clin Pathol; 2015 Feb; 68(2):93-9. PubMed ID: 25488926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
    Wolff AC; Hammond ME; Hicks DG; Dowsett M; McShane LM; Allison KH; Allred DC; Bartlett JM; Bilous M; Fitzgibbons P; Hanna W; Jenkins RB; Mangu PB; Paik S; Perez EA; Press MF; Spears PA; Vance GH; Viale G; Hayes DF; ;
    Arch Pathol Lab Med; 2014 Feb; 138(2):241-56. PubMed ID: 24099077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
    Wolff AC; Hammond ME; Hicks DG; Dowsett M; McShane LM; Allison KH; Allred DC; Bartlett JM; Bilous M; Fitzgibbons P; Hanna W; Jenkins RB; Mangu PB; Paik S; Perez EA; Press MF; Spears PA; Vance GH; Viale G; Hayes DF; ;
    J Clin Oncol; 2013 Nov; 31(31):3997-4013. PubMed ID: 24101045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reflex Repeat HER2 Testing of Grade 3 Breast Carcinoma at Excision Using Immunohistochemistry and In Situ Analysis: Frequency of HER2 Discordance and Utility of Core Needle Biopsy Parameters to Refine Case Selection.
    Prendeville S; Feeley L; Bennett MW; O'Connell F; Browne TJ
    Am J Clin Pathol; 2016 Jan; 145(1):75-80. PubMed ID: 26712873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted Therapy.
    Ballinger TJ; Sanders ME; Abramson VG
    Clin Breast Cancer; 2015 Jun; 15(3):171-80. PubMed ID: 25516402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia.
    Farshid G; Bilous M; Morey A; Fox S; Lakhani S; Loi S; Bell R; Spillane A
    Pathology; 2019 Jun; 51(4):345-348. PubMed ID: 31076089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
    van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
    Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy.
    Lee JA; Shaheen M; Walke T; Daly M
    Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):325-41. PubMed ID: 21671702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France].
    Penault-Llorca F; Vincent-Salomon A; MacGrogan G; Roger P; Treilleux I; Valent A; Mathieu MC; Antoine M; Becette V; Bor C; Brabencova E; Charafe-Jauffret E; Chenard MP; Dauplat MM; Delrée P; Devouassoux M; Fiche M; Fondrevelle ME; Fridman V; Garbar C; Genin P; Ghnassia JP; Haudebourg J; Laberge-Le Couteulx S; Loussouarn D; Maran-Gonzalez A; Marcy M; Michenet P; Poulet B; Sagan C; Trassard M; Verriele V; Arnould L; Lacroix-Triki M;
    Ann Pathol; 2014 Oct; 34(5):352-65. PubMed ID: 25439988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the Updated 2018 American Society of Clinical Oncology/College of American Pathologists Guideline for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.
    Li A; Bai Q; Kong H; Zhou S; Lv H; Zhong S; Li M; Bi R; Zhou X; Yang W
    Arch Pathol Lab Med; 2020 Sep; 144(9):1097-1107. PubMed ID: 32142367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies.
    Lebeau A; Turzynski A; Braun S; Behrhof W; Fleige B; Schmitt WD; Grob TJ; Burkhardt L; Hölzel D; Jackisch C; Thomssen C; Müller V; Untch M
    J Clin Oncol; 2010 Jul; 28(20):3264-70. PubMed ID: 20498397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comments on American Society of Clinical Oncology/College of American Pathologists for HER2 testing in breast cancer].
    Gong Y; Xiao CH; Fu L
    Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):795-8. PubMed ID: 20193452
    [No Abstract]   [Full Text] [Related]  

  • 20. HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy.
    Brunelli M; Manfrin E; Martignoni G; Bersani S; Remo A; Reghellin D; Chilosi M; Bonetti F
    Am J Clin Pathol; 2008 Jun; 129(6):907-11. PubMed ID: 18480007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.